Par Pharmaceutical Reports Fourth Quarter and Full Year 20...(250 Total operating expenses 54279 ...),Health

Total operating expenses 54,279 56,711 214,931 213,280

Gain on sale of product

rights - - 20,000 3,054

Operating income 3,568 2,242 73,588 7,722

Other (expense) income,

net (7) 60 (56) 126

Equity in loss of joint

venture (52) (166) (387) (663)

Gain (loss) on marketable

securities, net 3,060 3,190 (1,583) (583)

Interest income 3,408 2,919 13,673 8,974

Interest expense (1,667) (1,712) (6,803) (6,781)

Income from continuing

operations before

provision for income

taxes 8,310 6,533 78,432 8,795

Provision for income

taxes 2,781 1,488 27,322 2,054

Income from continuing

operations 5,529 5,045 51,110 6,741

Discontinued operations:

Income from discontinued

operations - - - -

Provision for income

taxes (Restated) 1,212 894 1,212 894

Loss from discontinued

operations (Restated) (1,212) (894) (1,212) (894)

Net income (Restated) $4,317 $4,151 $49,898 $5,847

Basic earnings per share

of common stock:

Income from continuing

operations $ 0.16 $0.15 $ 1.48 $ 0.20

Loss from discontinued

operations (Restated) (0.04) (0.03) (0.04) (0.03)

Net income (Restated) $ 0.12 $0.12 $ 1.44 $0.17

Diluted earnings per

share of common stock:

Income from continuing'/>"/>